Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics Granted FDA Fast Track for PSV359 in Solitary Fibrous Tumors

Neutral Impact 3 of 5 legal/regulatory Written later

Perspective Therapeutics (NYSE American: CATX) announced on October 8, 2026 that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The filing says the designation is intended to facilitate development and expedite review, and that PSV359 is in an ongoing Phase 1/2a study, but it does not describe any financial effect.

Key points

  • FDA granted Fast Track Designation for PSV359 on or before October 8, 2026, per the press release dated October 8, 2026.
  • The designation covers adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
  • PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study (NCT06710756).
  • The press release is filed as Exhibit 99.1; the filing reports no financial figures.

The filing

CompanyPerspective Therapeutics, Inc. (CATX)
Form8-K, current report
Filed with the SECOct 8, 2026, 6:28 AM ET
Accession number0001193125-26-417384

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.